Korean Circ J.  2019 Oct;49(10):975-986. 10.4070/kcj.2018.0391.

Procedural, Early and Long-term Outcomes after Percutaneous Closure of Atrial Septal Defect: Comparison between Large and Very Large Atrial Septal Defect Groups

• Jung SY
• Kim AY
• Jung JW
• Choi JY

• KMID: 2458006
• DOI: http://doi.org/10.4070/kcj.2018.0391

Abstract

BACKGROUND
This study aimed to compare procedural, early and long-term outcome of device closure of atrial septal defect (ASD) between large ASD patients and very large ASD patients.
METHODS
We carried a retrospective study of adult large ASD (defined as ≥25 mm) treated by percutaneous closure using Amplatzer septal occluder during 12-year period (May 2003-February 2015) at a single tertiary center. A total of 269 patients were divided into 2 groups, according to the pre-procedural maximal ASD diameter; 25 mm≤ASD<35mm, group 1 (n=216) and 35 mm≤ASD, group 2 (n=53). We compared procedural parameters, early complications and long-term follow-up results between 2 groups.
RESULTS
The need of modified implantation techniques (MITs) was higher group 2 (23.6% vs. 37.7%, p=0.034). Procedural success rate was considerably high in both groups (99.1% in group 1 vs. 100% in group 2, p=0.620). Major complications were occurred in 4 (1.5%) patients (1.4% vs. 1.9%, p=0.804). Minor complication rate was not different between 2 groups. During long-term follow-up (47.2±32.0 months, range, 6.0-135.5), there was one major complication (0.4%) of stroke. Most common long-term minor event was migraine headache (3.9%) followed by arrhythmias (1.9%) without statistical difference between 2 groups.
CONCLUSIONS
Although MIT was more frequently required in very large ASD groups, the procedural, early and long-term outcomes after percutaneous ASD closure were similar in both groups. This suggested that percutaneous ASD closure for very large ASD could be considered a good treatment option.

Keyword

Atrial septal defect; Septal occluder; Cardiac catheterization; Clinical outcomes

MeSH Terms

Adult
Arrhythmias, Cardiac
Cardiac Catheterization
Follow-Up Studies
Heart Septal Defects, Atrial*
Humans
Migraine Disorders
Retrospective Studies
Septal Occluder Device
Stroke

Figure

• 

  Figure 1 The fates of TR before procedure and at last follow-up. TR = tricuspid regurgitation.

Reference

1. King TD, Thompson SL, Steiner C, Mills NL. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA. 1976; 235:2506–2509.

2. Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K. Amplatzer Investigators. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol. 2002; 39:1836–1844.

3. Thomson JD, Aburawi EH, Watterson KG, Van Doorn C, Gibbs JL. Surgical and transcatheter (Amplatzer) closure of atrial septal defects: a prospective comparison of results and cost. Heart. 2002; 87:466–469.

4. Geva T, Martins JD, Wald RM. Atrial septal defects. Lancet. 2014; 383:1921–1932.

5. Feltes TF, Bacha E, Beekman RH 3rd, et al. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation. 2011; 123:2607–2652.

6. Kazmouz S, Kenny D, Cao QL, Kavinsky CJ, Hijazi ZM. Transcatheter closure of secundum atrial septal defects. J Invasive Cardiol. 2013; 25:257–264.

7. Everett AD, Jennings J, Sibinga E, et al. Community use of the Amplatzer atrial septal defect occluder: results of the multicenter MAGIC atrial septal defect study. Pediatr Cardiol. 2009; 30:240–247.

8. Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders. J Am Coll Cardiol. 2005; 45:505–507.

9. Moore J, Hegde S, El-Said H, et al. Transcatheter device closure of atrial septal defects: a safety review. JACC Cardiovasc Interv. 2013; 6:433–442.

10. Masura J, Gavora P, Formanek A, Hijazi ZM. Transcatheter closure of secundum atrial septal defects using the new self-centering Amplatzer septal occluder: initial human experience. Cathet Cardiovasc Diagn. 1997; 42:388–393.

11. Hellenbrand WE, Fahey JT, McGowan FX, Weltin GG, Kleinman CS. Transesophageal echocardiographic guidance of transcatheter closure of atrial septal defect. Am J Cardiol. 1990; 66:207–213.

12. Kim NK, Park SJ, Shin JI, Choi JY. Eight-French intracardiac echocardiography – safe and effective guidance for transcatheter closure in atrial septal defects –. Circ J. 2012; 76:2119–2123.

13. Asrress KN, Mitchell AR. Intracardiac echocardiography. Heart. 2009; 95:327–331.

14. Varma C, Benson LN, Silversides C, et al. Outcomes and alternative techniques for device closure of the large secundum atrial septal defect. Catheter Cardiovasc Interv. 2004; 61:131–139.

15. Dalvi BV, Pinto RJ, Gupta A. New technique for device closure of large atrial septal defects. Catheter Cardiovasc Interv. 2005; 64:102–107.

16. Pillai AA, Rangaswamy Balasubramanian V, Selvaraj R, Saktheeswaran M, Satheesh S, Jayaraman B. Utility of balloon assisted technique in trans catheter closure of very large (≥35 mm) atrial septal defects. Cardiovasc Diagn Ther. 2014; 4:21–27.

17. Narin N, Baykan A, Argun M, et al. New modified balloon-assisted technique to provide appropriate deployment in the closure of large secundum atrial septal defect using Amplatzer septal occluder in children. J Invasive Cardiol. 2014; 26:597–602.

18. Rodríguez M, Suárez de Lezo J, Pan M, et al. Percutaneous closure of large atrial septal defects. Rev Esp Cardiol. 2003; 56:888–893.

19. Romanelli G, Harper RW, Mottram PM. Transcatheter closure of secundum atrial septal defects: results in patients with large and extreme defects. Heart Lung Circ. 2014; 23:127–131.

20. Baruteau AE, Petit J, Lambert V, et al. Transcatheter closure of large atrial septal defects: feasibility and safety in a large adult and pediatric population. Circ Cardiovasc Interv. 2014; 7:837–843.

21. Abaci A, Unlu S, Alsancak Y, Kaya U, Sezenoz B. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies. Catheter Cardiovasc Interv. 2013; 82:1123–1138.

22. El-Said H, Hegde S, Foerster S, et al. Device therapy for atrial septal defects in a multicenter cohort: acute outcomes and adverse events. Catheter Cardiovasc Interv. 2015; 85:227–233.

23. Wahab HA, Almossawy A, Al Bitar I, Hijazi ZM. Tips and tricks to prevent prolapse of the Amplatzer septal occluder through large atrial septal defects. Catheter Cardiovasc Interv. 2011; 78:1041–1044.

24. Amin Z. Transcatheter closure of secundum atrial septal defects. Catheter Cardiovasc Interv. 2006; 68:778–787.

25. Lopez K, Dalvi BV, Balzer D, et al. Transcatheter closure of large secundum atrial septal defects using the 40 mm Amplatzer septal occluder: results of an international registry. Catheter Cardiovasc Interv. 2005; 66:580–584.

26. Amoozgar H, Ahmadipoor M, Amirghofran AA. Complete heart block following transcatheter closure of atrial septal defect due to growth of inflammatory tissue. Pediatr Cardiol. 2014; 35:1301–1303.

27. Rohit MK, Puri K, Vadivelu R. Reversible complete atrioventricular block after percutaneous ASD device closure in a child <15 kg. Indian Heart J. 2014; 66:366–369.

28. Nyboe C, Olsen MS, Nielsen-Kudsk JE, Hjortdal VE. Atrial fibrillation and stroke in adult patients with atrial septal defect and the long-term effect of closure. Heart. 2015; 101:706–711.

29. Wang C, Zhao SH, Jiang SL, et al. Prevalence and risk factors of atrial tachyarrhythmia before and after percutaneous closure of secundum atrial septal defect in patients over 40 years of age. Zhonghua Xin Xue Guan Bing Za Zhi. 2007; 35:797–801.

30. Rodés-Cabau J, Mineau S, Marrero A, et al. Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale. Am J Cardiol. 2008; 101:688–692.

31. Rodés-Cabau J, Molina C, Serrano-Munuera C, et al. Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheter Cardiovasc Interv. 2003; 60:540–542.

32. Mortelmans K, Post M, Thijs V, Herroelen L, Budts W. The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J. 2005; 26:1533–1537.

33. Du ZD, Cao QL, Koenig P, Heitschmidt M, Hijazi ZM. Speed of normalization of right ventricular volume overload after transcatheter closure of atrial septal defect in children and adults. Am J Cardiol. 2001; 88:1450–1453. A9

34. Veldtman GR, Razack V, Siu S, et al. Right ventricular form and function after percutaneous atrial septal defect device closure. J Am Coll Cardiol. 2001; 37:2108–2113.

35. Balint OH, Samman A, Haberer K, et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure. Heart. 2008; 94:1189–1193.

36. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction. Circulation. 1987; 76:1037–1042.

37. Cherian G, Uthaman CB, Durairaj M, et al. Pulmonary hypertension in isolated secundum atrial septal defect: high frequency in young patients. Am Heart J. 1983; 105:952–957.